Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer.
Author
Zaidi, SobiaAmdur, Richard
Xiang, Xiyan
Yu, Herbert
Wong, Linda L
Rao, Shuyun
He, Aiwu R
Amin, Karan
Zaheer, Daewa
Narayan, Raj K
Satapathy, Sanjaya K
Latham, Patricia S
Shetty, Kirti
Guha, Chandan
Gough, Nancy R
Mishra, Lopa
Date
2022-06-06Journal
Genes & CancerPublisher
SAGE Publications Inc.Type
Article
Metadata
Show full item recordSee at
https://doi.org/10.18632/genesandcancer.220http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9170384/
Abstract
Hepatocellular carcinoma (HCC) is the primary form of liver cancer and a major cause of cancer death worldwide. Early detection is key to effective treatment. Yet, early diagnosis is challenging, especially in patients with cirrhosis, who are at high risk of developing HCC. Dysfunction or loss of function of the transforming growth factor β (TGF-β) pathway is associated with HCC. Here, using quantitative immunohistochemistry analysis of samples from a multi-institutional repository, we evaluated if differences in TGF-β receptor abundance were present in tissue from patients with only cirrhosis compared with those with HCC in the context of cirrhosis. We determined that TGFBR2, not TGFBR1, was significantly reduced in HCC tissue compared with cirrhotic tissue. We developed an artificial intelligence (AI)-based process that correctly identified cirrhotic and HCC tissue and confirmed the significant reduction in TGFBR2 in HCC tissue compared with cirrhotic tissue. Thus, we propose that a reduction in TGFBR2 abundance represents a useful biomarker for detecting HCC in the context of cirrhosis and that incorporating this biomarker into an AI-based automated imaging pipeline could reduce variability in diagnosing HCC from biopsy tissue.Identifier to cite or link to this item
http://hdl.handle.net/10713/19126ae974a485f413a2113503eed53cd6c53
10.18632/genesandcancer.220
Scopus Count
Collections
Related articles
- Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.
- Authors: Mamiya T, Yamazaki K, Masugi Y, Mori T, Effendi K, Du W, Hibi T, Tanabe M, Ueda M, Takayama T, Sakamoto M
- Issue date: 2010 Sep
- Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma.
- Authors: Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z
- Issue date: 2020 Jun 16
- Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.
- Authors: Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L
- Issue date: 2020 Jan
- Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
- Authors: Ji GZ, Wang XH, Miao L, Liu Z, Zhang P, Zhang FM, Yang JB
- Issue date: 2006 Jan 28
- Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
- Authors: El-Bassiouny AE, Zoheiry MM, Nosseir MM, El-Ahwany EG, Ibrahim RA, El-Bassiouni NE
- Issue date: 2007 Aug 28